Cubicin RF - (500 mg/vial; Powder, Intravenous)

Generic Name	Daptomycin	**Innovator**	CUBIST Pharma
Dosage	500 mg/vial; Powder, Intravenous	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	Indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin- susceptible and methicillin-resistant isolates		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.